Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 11, 2019. The report discloses the grant of conditional share awards to Executive Directors and Persons Discharging Managerial Responsibilities (PDMRs) under the GlaxoSmithKline 2017 Performance Share Plan. The awards were granted on March 8, 2019, with a performance period spanning three financial years from January 1, 2019, to December 31, 2021.
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. Instead, it details specific performance targets and transaction values related to executive compensation:
- Adjusted Free Cash Flow (AFCF) Targets: The vesting schedule for the AFCF measure is based on targets ranging from a threshold of £11.74 billion (25% vesting) to a maximum of £13.91 billion (100% vesting).
- Transaction Prices: Awards were valued at £15.124 per Ordinary Share and $40.12 per American Depositary Share (ADS) on the grant date.
- Total Award Volume: The filing lists individual award volumes for 13 executives, totaling approximately 1,785,921 Ordinary Shares and 468,854 ADSs.
Material Changes
The filing notes a specific revision to the Relative Total Shareholder Return (TSR) vesting schedule compared to the previous year's award. The 2019 awards now include a threshold vesting level of 25% for achieving median performance (ranking 5th in a group of 10), whereas previous structures may have differed. The TSR comparator group remains unchanged, consisting of nine other global pharmaceutical companies plus GSK.
Guidance, Outlook, and Risks
Performance Measures: The 2019 awards are equally weighted across three measures:
- Relative TSR (1/3): Compares GSK's TSR against a peer group. Vesting ranges from 0% (6th or below) to 100% (1st-3rd).
- Adjusted Free Cash Flow (1/3): Focuses on working capital management and cash generation. Vesting is linear between the threshold (£11.74bn) and maximum (£13.91bn).
- R&D New Product Performance (1/3): Specific targets are withheld due to commercial sensitivity. Vesting ranges from 0% (below threshold) to 100% (exceeding 122% of the threshold).
Risks and Contingencies: Unvested awards will lapse at the end of the performance period. Executive Directors face an additional two-year vesting period (five years total), during which shares are forfeited only if terminated for cause. Dividends accrue on awards but only vest if the underlying shares vest.
Investor Verification Checklist
- Verify the specific R&D new product targets once disclosed at the end of the 2021 performance period.
- Monitor GSK's Adjusted Free Cash Flow performance against the £11.74bn to £13.91bn range to determine vesting outcomes.
- Track GSK's TSR ranking relative to the defined peer group (AstraZeneca, BMS, Eli Lilly, J&J, Merck, Novartis, Pfizer, Roche, Sanofi) to assess the Relative TSR component.
- Confirm the final vesting status of the awards granted on March 8, 2019, upon the conclusion of the performance period in December 2021.